ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

Company Overview

ENDRA Life Sciences, Inc. (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems. Using patented algorithms and specialized hardware, the system captures thermoacoustic signals generated when tissue is exposed to low-power microwave pulses. These signals enable clinicians to visualize temperature distributions during procedures such as radiofrequency ablation, microwave ablation and high-intensity focused ultrasound. The company collaborates with hospitals, academic research centers and medical device partners to conduct preclinical and clinical studies that validate the performance and utility of TAEUS technology.

The company holds a growing portfolio of issued and pending patents across the United States, Europe and Asia, and it is advancing toward broader regulatory clearances and international market entry. ENDRA’s leadership team is led by President and Chief Executive Officer David Kaiss, who brings two decades of experience in medical device development, regulatory affairs and commercialization. Under his direction, the company has expanded its R&D capabilities, strengthened manufacturing partnerships and established key distribution channels to support future product launches.

Key Stats

• Today's Range: $4.87 to $4.91
• 50-Day Range: $4.09 to $8.84
• 52-Week Range: $2.90 to $22.68
• Volume: 5,261 shs
• Average Volume: 643,731 shs
• Market Capitalization: $3.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Buy

ENDRA Life Sciences Stock Analysis - MarketRank™

ENDRA Life Sciences scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

ENDRA Life Sciences has a consensus price target of $50.00, representing about 940.6% upside from its current price of $4.81.

Amount of Analyst Coverage

ENDRA Life Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($47.46) to ($15.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ENDRA Life Sciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ENDRA Life Sciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ENDRA Life Sciences has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.65% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 19.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ENDRA Life Sciences does not currently pay a dividend.

Dividend Growth

ENDRA Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.65% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 19.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

ENDRA Life Sciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ENDRA Life Sciences this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for NDRA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.04% of the stock of ENDRA Life Sciences is held by insiders.

Percentage Held by Institutions

Only 1.19% of the stock of ENDRA Life Sciences is held by institutions.

NDRA Stock Analysis - Frequently Asked Questions

How have NDRA shares performed this year?

ENDRA Life Sciences' stock was trading at $6.26 on January 1st, 2025. Since then, NDRA stock has decreased by 23.2% and is now trading at $4.8050.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($1.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $0.56.

When did ENDRA Life Sciences' stock split?

ENDRA Life Sciences's stock reverse split on Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did ENDRA Life Sciences IPO?

ENDRA Life Sciences (NDRA) raised $10 million in an IPO on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NDRA
• CIK: 1681682
• Web: www.endrainc.com
• Phone: (734) 335-0468
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ENDRA Life Sciences: $50.00
• High Price Target: $50.00
• Low Price Target: $50.00
• Potential Upside/Downside: +926.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($33.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -194.14%
• Return on Assets: -127.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.21
• Quick Ratio: 3.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.77 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 750,000
• Free Float: 753,000
• Market Cap: $3.65 million
• Optionable: Not Optionable
• Beta: -0.14